Citation Impact
Citing Papers
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
2017 Standout
Removing T-cell epitopes with computational protein design
2014 StandoutNobel
Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival
2008
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
2016 Standout
FGFR2 -Amplified Gastric Cancer Cell Lines Require FGFR2 and Erbb3 Signaling for Growth and Survival
2008
Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer
2011 Standout
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
2010 Standout
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
2018 Standout
Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
2014
Cancer statistics, 2022
2022 Standout
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study
2014
Microenvironmental regulation of tumour angiogenesis
2017
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
Gastric cancer
2016 Standout
Cancer Statistics, 2021
2021 Standout
Docetaxel Nanotechnology in Anticancer Therapy
2012
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
2006 Standout
Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur–0.4M gimestat–1M otastat potassium) in advanced gastric cancer patients
1998
Irinotecan in the treatment of gastric cancer
2003
Mechanism and medical implications of mammalian autophagy
2018 Standout
Activation of c-K-ras mutations in human gastrointestinal tumors
2000
The biology and management of non-small cell lung cancer
2018 StandoutNature
Phase II Trial of XELOX as First-Line Treatment for Patients with Advanced Gastric Cancer
2010
Nodular Lymphocyte Predominant Hodgkin Lymphoma and T Cell/Histiocyte Rich Large B Cell Lymphoma - Endpoints of a Spectrum of One Disease?
2013
Transforming Growth Factor-β Signaling in Immunity and Cancer
2019 Standout
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial
2009
PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma
2016
Radiolabeled immunotherapy in non-Hodgkin's lymphoma treatment: the next step
2009
Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning
2018 Standout
Population Pharmacokinetics of Pegylated Liposomal CKD‐602 (S‐CKD602) in Patients With Advanced Malignancies
2011
Phase II Clinical Trial of Genexol(R) (Paclitaxel) and Carboplatin for Patients with Advanced Non-small Cell Lung Cancer
2011
A randomized phase II trial of S-1-oxaliplatin versus capecitabine–oxaliplatin in advanced gastric cancer
2012
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
2015 Standout
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
Hepatitis B virus infection
2009 Standout
Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
2014 Standout
Esophageal Cancer
2003 Standout
Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy
2016
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
2009 Standout
Clinical applications of quinone-containing alkylating agents
2000
Chemotherapy for advanced gastric cancer
2010
Chemotherapy for advanced gastric cancer
2005
Lung cancer: current therapies and new targeted treatments
2016 Standout
Fibroblast growth factor signalling: from development to cancer
2010 Standout
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study
2009
Hepatitis B reactivation after chemotherapy: two decades of clinical research
2008
Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine
2007 Standout
Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil
2006
Chronic hepatitis B
2007 Standout
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles
1998
Chronic hepatitis B: Update 2009 #
2009 Standout
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
2012 Standout
Tumour-associated macrophages as treatment targets in oncology
2017 Standout
Gastric cancer
2020 Standout
Targeting autophagy in cancer
2017 Standout
Infections in Patients with Multiple Myeloma in the Era of High‐Dose Therapy and Novel Agents
2009
Neutrophils in cancer: neutral no more
2016 Standout
Cytotoxic T-cell and NK-cell Lymphomas
2014
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
2008 Standout
Functional Relationship between Tumor-Associated Macrophages and Macrophage Colony-Stimulating Factor as Contributors to Cancer Progression
2014
Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction
2008
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Gefitinib for non-small-cell lung cancer treatment
2011
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Docetaxel (Taxotere®)-cisplatin (TC): An effective drug combination in gastric carcinoma
2000
Factor V Leiden: A Clinical Review
2001
A Phase I Study of Pemetrexed, Carboplatin, and Concurrent Radiotherapy in Patients with Locally Advanced or Metastatic Non–Small Cell Lung or Esophageal Cancer
2007
A randomized multi-center phase II trial of capecitabine (X) versus S-1 (S) as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer
2007
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
2017 Standout
ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic)
2006 Standout
Randomized Phase III Trial of Fluorouracil Alone Versus Fluorouracil Plus Cisplatin Versus Uracil and Tegafur Plus Mitomycin in Patients With Unresectable, Advanced Gastric Cancer: The Japan Clinical Oncology Group Study (JCOG9205)
2002
Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group
2006 Standout
Antitumor Antibiotics: Bleomycin, Enediynes, and Mitomycin
2005 Standout
Randomized Multicenter Phase II Trial of a Biweekly Regimen of Fluorouracil and Leucovorin (LV5FU2), LV5FU2 Plus Cisplatin, or LV5FU2 Plus Irinotecan in Patients With Previously Untreated Metastatic Gastric Cancer: A Fédération Francophone de Cancérologie Digestive Group Study—FFCD 9803
2004
NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology
2011
Clinical relevance of autophagic therapy in cancer: Investigating the current trends, challenges, and future prospects
2016
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies
2017 StandoutNobel
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohort
2015
Entecavir vs Lamivudine for Prevention of Hepatitis B Virus Reactivation Among Patients With Untreated Diffuse Large B-Cell Lymphoma Receiving R-CHOP Chemotherapy
2014
Chemotherapy for advanced gastric cancer
2017 Standout
Disparities in Gastric Cancer Chemotherapy Between the East and West
2006
Phase III Study of Cisplatin, Etoposide, and Concurrent Chest Radiation With or Without Consolidation Docetaxel in Patients With Inoperable Stage III Non–Small-Cell Lung Cancer: The Hoosier Oncology Group and U.S. Oncology
2008
Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update
2017 Standout
Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial).
2006
Targeted therapies for treatment of non‐small cell lung cancer—Recent advances and future perspectives
2015
Treatment of Hematologic Malignancies with Immunotoxins and Antibody-Drug Conjugates
2011
Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy
2006
Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity
2014
A multi-center, late phase II clinical trial of Genexol® (paclitaxel) and cisplatin for patients with advanced gastric cancer
2004
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer
2008
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
2014 Standout
How I treat multiple myeloma in younger patients
2009
Contribution of Dexamethasone to Control of Chemotherapy-Induced Nausea and Vomiting: A Meta-Analysis of Randomized Evidence
2000
Systematic Review: The Effect of Preventive Lamivudine on Hepatitis B Reactivation during Chemotherapy
2008
BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD
2014
Multiple Myeloma
2011 Standout
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
2015
Why, When, and How to Prevent Hepatitis B Virus Reactivation in Cancer Patients Undergoing Chemotherapy
2011
Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.
2015
The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group
2003 Standout
Prospective Randomized Trial Comparing Mitomycin, Cisplatin, and Protracted Venous-Infusion Fluorouracil (PVI 5-FU) With Epirubicin, Cisplatin, and PVI 5-FU in Advanced Esophagogastric Cancer
2002
Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation
2016
Evaluation of the efficacy and toxicity of protocol cisplatin, 5-fluorouracil, leucovorin compared to protocol fluorouracil, doxorubicin and mitomycin C in locally advanced and metastatic gastric cancer
2012
Works of Cheolwon Suh being referenced
Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study
2007
Autophagic Markers BECLIN 1 and LC3 Are Associated with Prognosis of Multiple Myeloma
2015
A phase I study of everolimus and CHOP in newly diagnosed peripheral T-cell lymphomas
2013
Phase II study of radiotherapy with three-dimensional conformal boost concurrent with paclitaxel and cisplatin for Stage IIIB non–small-cell lung cancer
2005
Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP
2010
CD163 Expression Was Associated with Angiogenesis and Shortened Survival in Patients with Uniformly Treated Classical Hodgkin Lymphoma
2014
Clinicopathologic significance of the K-ras gene codon 12 point mutation in stomach cancer. An analysis of 140 cases
1995
Bortezomib and the Increased Incidence of Herpes Zoster in Patients with Multiple Myeloma
2008
Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: analysis of clinical features and outcomes from the Asia Lymphoma study group
2013
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer
1993
Complete Remission Status before Autologous Stem Cell Transplantation Is an Important Prognostic Factor in Patients with Multiple Myeloma Undergoing Upfront Single Autologous Transplantation
2009
A Randomized Double-Blind Trial of Ondansetron Alone Versus in Combination with Dexamethasone Versus in Combination with Dexamethasone and Lorazepam in the Prevention of Emesis Due to Cisplatin-Based Chemotherapy
1994
Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Korean patients with deep vein thrombosis
1998
A phase I trial to determine the maximum tolerated dose and evaluate the safety and pharmacokinetics (PK) of docetaxel-PNP, polymeric nanoparticle formulation of docetaxel, in subjects with advanced solid malignancies.
2012
CSF-1R Expression in Tumor-Associated Macrophages Is Associated With Worse Prognosis in Classical Hodgkin Lymphoma
2014
PD4-1-7: Consolidation chemotherapy with monthly Paclitaxel and Cisplatin (PC) or observation after concurrent chemoradiotherapy for locally advanced non-small cell lung cancer (NSCLS): Randomized phase II study
2007
Phase II Study of S-1 Plus Either Irinotecan or Docetaxel for Non-small Cell Lung Cancer Patients Treated with More Than Three Lines of Treatment
2011
Extranodal Natural Killer T-Cell Lymphoma, Nasal-Type: A Prognostic Model From a Retrospective Multicenter Study
2005
The Prophylactic Use of Lamivudine Can Maintain Dose-Intensity of Adriamycin in Hepatitis-B Surface Antigen (HBs Ag)-positive Patients with Non-Hodgkin's Lymphoma Who Receive Cytotoxic Chemotherapy
2003
Multicenter Phase II Trial of 90Y-Ibritumomab Tiuxetan with High-Dose Chemotherapy (Busulfan/Cyclophosphamide/Etoposide) Followed by Autologous Stem Cell Transplantation in Relapsed, Refractoried, or High-Risk B-Cell NHL.
2007
Induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) versus CCRT alone for unresectable stage III non-small cell lung cancer (NSCLC): Randomized phase III trial
2007
Complete Remission Status at Autologous Transplantation Is an Important Prognostic Factor in Multiple Myeloma Patients Received Upfront Single Autologous Transplantation.
2007
The Ratio of the Absolute Lymphocyte Count to the Absolute Monocyte Count Is Associated with Prognosis in Hodgkin's Lymphoma: Correlation with Tumor-Associated Macrophages
2012
Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group Study
2011
Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab In Relapsed DLBCL Patients Followed by Stem Cell Transplantation: Preliminary Safety and Efficacy
2010
Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
2013
A Multi-Center, Phase II Clinical Trial of Genexol(R) (Paclitaxel) and Cisplatin for Patients with Non-Small Cell Lung Cancer
2003
Prognostic Significance of the Ratio of Absolute Neutrophil Count to Absolute Lymphocyte Count in Classic Hodgkin Lymphoma
2012
Randomized Phase III Trial of Gefitinib versus Docetaxel in Non–Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy
2010